Algert Global LLC Boosts Stake in Arvinas, Inc. (NASDAQ:ARVN)

Algert Global LLC boosted its position in Arvinas, Inc. (NASDAQ:ARVN) by 22.6% during the fourth quarter, Holdings Channel reports. The fund owned 205,988 shares of the company’s stock after acquiring an additional 37,927 shares during the period. Algert Global LLC’s holdings in Arvinas were worth $3,949,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ARVN. Vanguard Group Inc. lifted its position in Arvinas by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock worth $135,389,000 after buying an additional 56,561 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock worth $78,656,000 after acquiring an additional 249,295 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arvinas in the 4th quarter valued at $42,332,000. ArrowMark Colorado Holdings LLC grew its holdings in shares of Arvinas by 42.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company’s stock valued at $34,057,000 after purchasing an additional 532,105 shares during the last quarter. Finally, New Leaf Venture Partners L.L.C. raised its position in Arvinas by 10.5% in the 4th quarter. New Leaf Venture Partners L.L.C. now owns 1,585,721 shares of the company’s stock worth $30,398,000 after purchasing an additional 151,000 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. The trade was a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,230 shares of company stock valued at $769,402 in the last 90 days. Corporate insiders own 5.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $10.00 price objective (down from $52.00) on shares of Arvinas in a research note on Friday, May 2nd. Wells Fargo & Company decreased their price target on Arvinas from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Morgan Stanley dropped their price objective on Arvinas from $48.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, March 13th. TD Cowen downgraded shares of Arvinas from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Finally, Guggenheim dropped their price target on shares of Arvinas from $32.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.97.

Arvinas Trading Down 8.9 %

Shares of ARVN stock opened at $6.95 on Wednesday. The company’s fifty day moving average price is $9.26 and its 200-day moving average price is $17.16. The stock has a market cap of $507.29 million, a PE ratio of -2.51 and a beta of 2.21. Arvinas, Inc. has a 12 month low of $5.94 and a 12 month high of $37.38.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the firm earned ($0.97) EPS. The company’s quarterly revenue was up 646.2% compared to the same quarter last year. On average, sell-side analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.